🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phase 1 trial (PK) twincretin survodutide 1⃣Child A /B /C cirrhosis vs healthy 📌AUC and Cmax similar 2⃣ Overweight Child A/ B cirhosis vs non-cirrhotic 📌once-weekly s.c. escalation over 24 w AEs comparable 🏁improvement of NITs 📝 GLP(+) in cirrhosis doi.org/10.1016/j.jhep…

Researchers discuss that HIV is not associated with a higher rate of major adverse liver outcomes including HCC, in comparison to those without HIV in patients with underlying chronic liver disease. Maurice Michel Jörn Schattenberg Check out more from GHA 🔗ow.ly/aSq850TfIZN

Non-Invasive CSPH Estimated Risk (NICER) model including Echosens SSM by VCTE at 100Hz 👉Developed (2020-2022) & validated (2023) in contemporary pts. 👉Outperforms ANTICIPATE(-NASH): AUC consistently >0.9. 👉Well-calibrated. 👉Sets a new standard IMHO. #LiverTwitter 🔗👇

So proud of my friend Jörn Schattenberg for being elected to this prestigious position. Mazen Noureddin, MD, MHSc Alina Allen Sonal Kumar, MD MPH AASLD President EASL Education Madrigal Pharmaceuticals Juan Pablo (JP) Arab, MD  Marco Arrese, MD Arizona Liver Health Novo Nordisk

Angelo Armandi, MD, PhD presenting on the 🔥 topic of MetALD! This condition affects 2-4% of the adult population in the US. Worse prognosis than MASLD, increasing cause for liver transplant! How to design MetALD trials?? Juan Pablo (JP) Arab, MD  Elliot Tapper Mazen Noureddin, MD, MHSc Novo Nordisk

🔝Pay tribute to my_UEG Scientific Committee 🌠They create #UEGWeek2024 🙏 Every year better 📶 The bar is high Jörn Schattenberg ! 🔗 Look forward for close collaboration

What’s up in #MASH #treatment⁉️ #ElisabettaBugianesi and Naim Alkhouri presenting 🗣️#novel 💊➕💉 and response Myself added 👨‍💻📈 #NIT to treatment from #resmetirom and #semaglutide my_UEG Rohit Loomba Manal Abdelmalek Elliot Tapper Mazen Noureddin, MD, MHSc Phil Newsome Quentin M. Anstee 🪑@HannesHagstrom

Learn how through joint efforts, policy makers can take steps to help prevent, diagnose and treat #liverdisease, reducing the extensive health and economic impacts econimpact.co/DE Supported by ISGlobal

#Nutrition and #weight loss from medical therapy 💉 🔥 topic ❓role of surgery my_UEG Shira zelber sagi @HannesHagstrom with 🔝 faculty #VerneaKeller Universität Saarland #mary-elizabethPatti Joslin Diabetes Center and #RubenNougeiras 🙌 ➡️ individualisation is 🗝️

⭐️We are proud to announce that Prof. Dr. Jörn Schattenberg, Director of the Department of Internal Medicine II at Saarland University Hospital, has been elected Chairman of the Scientific Committee of the United European Gastroenterology my_UEG for the term 2026 - 2029! 👏

👇

EASLnews Aleksander Krag Sven Francque APDP Diabetes Paul Brennan Maja Thiele Jörn Schattenberg Naim Alkhouri Maru Rinella MD FattyLiverAlliance Francesco Paolo Russo Ajay Duseja Arun J. Sanyal @HannesHagstrom Ramon Bataller ELISA POSE Luis Antonio Díaz, MD Brett E Fortune MD Alina Allen Mads Israelsen Tom Hemming Karlsen Mazen Noureddin, MD, MHSc Melina Manolas, MD, MPH Manuel Romero-Gómez Javier Crespo FDA Jordi Gracia-Sancho Juan Pablo (JP) Arab, MD  Javier Ampuero Juan M Pericas AASLD American Gastroenterological Association (AGA) Luca Valenti Shira zelber sagi European Liver Patients' Association Scott Isaacs Dr Jörn Schattenberg presenting at the #SLDsummit on drug approvals Europe and the importance of diet and physical activity. Thank you for showing our article on social nutrition: nature.com/articles/s4385…

The approval of new drugs for SLD will significantly impact the field, driving a shift towards a more proactive approach to liver health. While challenges remain in terms of healthcare systems and reimbursement, the availability of effective treatments offers a crucial

Kicking off #UEGWeek 2026! The work on the Scientific Programme for #UEGWeek 2026 is underway! Huge thanks to all SciComm members and new chairs, Jörn Schattenberg (SciComm) & maura corsetti (PGT), for their dedication. Two days of exciting collaboration, ideas and discussions!

Prevention to maintain GI Health 👨‍⚕️ Join me in #Homburg 🇩🇪 in person or online 💻 tonight 🌚 BV Prävention und Gesundheitsförderung Felix Burda Stiftung ❗️Patient information event ❗️ #empowerment European Liver Patients' Association Arbeitsgemeinschaft Junge Gastroenterologie (JuGa) my_UEG EASLnews uks.eu/ueber-das-uks/…

Addressing the rising global burden of #MASLD from the payors' perspective. Jeffrey V. Lazarus zobair younossi Jörn Schattenberg Rohit Loomba Alina Allen onlinelibrary.wiley.com/doi/10.1111/ap…

🟪NEW Article in press❕ The Weight of Choices: Prioritizing Lifestyle Over GLP-1 Receptor Agonist Therapy in Managing #MASLD 🔓#OpenAccess at 👉jhep-reports.eu/article/S2589-… #LiverTwitter

#LIVERAIM networking session is starting at track hub8! Join us and learn from Jörn Schattenberg and ELISA POSE how #biomarkers of #liverfibrosis can reshapethe future of Hepatology #livertwitter #EASLCongress Innovative Health Initiative EASL Education EASLnews Aleksander Krag Jeffrey V. Lazarus Maja Thiele

Did you know that #compensated #cirrhosis in MASH can be reversed from pharmacological treatment ⁉️ Shown at EASL Education EASLnews today in the General Session and Published online by Mazen Noureddin, MD, MHSc nejm.org/doi/full/10.10…

Kicking off the Global Think Tank on Steatotic Liver Disease #SLD in beautiful Barcelona. This is the “most interactive meeting” in hepatology. Jörn Schattenberg Scott Isaacs FattyLiverAlliance Perspectum Echosens Madrigal Pharmaceuticals